<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:type="http:///org/apache/uima/trials/type.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <tcas:DocumentAnnotation xmi:id="1" sofa="6" begin="0" end="1192" language="x-unspecified"/>
    <type:ORR xmi:id="13" sofa="6" begin="665" end="670"/>
    <type:PFSMean xmi:id="17" sofa="6" begin="777" end="795"/>
    <type:OSTime xmi:id="21" sofa="6" begin="797" end="805"/>
    <type:OSTime xmi:id="29" sofa="6" begin="848" end="856"/>
    <type:OSRate xmi:id="25" sofa="6" begin="837" end="842"/>
    <type:OSRate xmi:id="33" sofa="6" begin="860" end="865"/>
    <cas:Sofa xmi:id="6" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="OBJECTIVE: To investigate the efficacy and safety of goserelin plus anastrozole&#13;&#10;in advanced premenopausal breast cancer patients.&#13;&#10;METHODS: We summarized a single-centre experience with goserelin plus anastrozole&#13;&#10;in 32 premenopausal women with metastatic breast cancer (MBC). All patients&#13;&#10;received goserelin 3.6 mg by subcutaneous injection every 4 weeks concurrently&#13;&#10;with anastrozole 1 mg daily. The median duration of treatment was 12 months.&#13;&#10;RESULTS: No patient achieved complete remission (CR) (0%), 6 partial remissions&#13;&#10;(PR) (18.8%), 21 stable diseases (SD) (65.6%) and 5 progressive diseases (PD)&#13;&#10;(15.6%). Objective response rate (ORR) was achieved in 18.8% and clinical benefit&#13;&#10;(CR + PR + SD &gt; 6 months) in 68.8%. The median progression-free survival (PFS)&#13;&#10;was 12 (2 - 57) months. One-year overall survival rate (OS) was 87.4% and&#13;&#10;two-year OS 66.9%. The OS of patients without visceral metastasis was&#13;&#10;significantly longer than that of patients with visceral metastasis (P = 0.04).&#13;&#10;Hot flushes and nausea were predominant toxicities.&#13;&#10;CONCLUSION: The combination of goserelin and anastrozole appears to be an&#13;&#10;efficient and well-tolerated regimen in premenopausal MBC women."/>
    <cas:View sofa="6" members="1 13 17 21 29 25 33"/>
</xmi:XMI>
